The course of differentiated thyroid microcarcinoma in patients treated by different therapeutic strategies

Czech version

Authors: Marianna Grigerová ^1,2; Martin Griger ³; Emília Mojtová ^1,2; Ján Podoba ^1,2
Authors‘ workplace: Klinika endokrinológie LF SZU, Bratislava, Slovenská republika ¹; Onkologický ústav svätej Alžbety, s. r. o, Bratislava, Slovenská republika ²; EuroPainClinics Bratislava, Slovenská republika ³
Published in: Vnitř Lék 2016; 62(Suppl 3): 17-21
Category: Original Contributions

Overview

Low risk differentiated thyroid microcarcinoma therapy is a controversial area of thyroid tumor management. Major international medical societies and reputable institutes consider lobectomy to be sufficient therapeutic intervention for the pT1a cN0cM0 stage of papillary thyroid microcarcinoma. However different views and therapeutic strategies exist and result in unnecessary overtreatment and worsening of patient’s quality of life. We researched the course of the differentiated thyroid microcarcinoma in patients using different therapeutic strategies: lobectomy, total thyroidectomy, total thyroidectomy with central compartment prophylactic lymphadenectomy and total thyroidectomy followed by radioactive iodine treatment. Apart from an excellent prognosis we did not find out any clinically significant differences in the course of the disease. We can conclude that lobectomy is sufficient therapeutic intervention for patients with differentiated thyroid microcarcinoma without known metastases.

Key words:
differentiated thyroid microcarcinoma – management – overtreatment – the course of the disease

Sources

1. Baudin E, Travagli JP, Ropers J et al. Microcarcinoma of the thyroid gland. Cancer 1998; 83(3): 553–559.

2. Lee J, Rhee Y, Lee S et al. Frequent, Aggressive Behaviors of Thyroid Microcarcinomas in Korean Patients. Endocr J 2006; 53(5): 627–632.

3. Rodriguez JM, Moreno A, Parrilla P et al. Papillary thyroid microcarcinoma: clinical study and prognosis. Eur J Surg. 1997; 163(4): 255–259.

4. Pacini F, Schlumberger M, Dralle H et al. [European Thyroid Cancer Taskforce]. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154(6): 787–803. Erratum in Eur J Endocrinol 2006; 155(2): 385.

5. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26(1): 1–133. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2015.0020>.

6. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17(8): 873–890. Erratum in Stat Med 1999; 18(10): 1293.

7. Sugitani I, Toda K, Yamada K et al. Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes. World J Surg 2010; 34(6): 1222–1231.

8. Ito Y, Miyauchi A, Kihara M et al. Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation. Thyroid 2014; 24(1): 27–34. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2013.0367>.

9. Oda H, Miyauchi A, Ito Y et al. Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. Thyroid 2016; 26(1): 150–155. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2015.0313>.

10. Takami H, Ito Y, Okamoto T et al. Therapeutic Strategy for Differentiated Thyroid Carcinoma in Japan Based on a Newly Established Guideline Managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg 2010; 35(1): 111–121. Dostupné z DOI: <http://dx.doi.org/10.1007/s00268–010–0832–6>.

11. Wada N, Duh QY, Sugino K et al. Lymph Node Metastasis From 259 Papillary Thyroid Microcarcinomas: Frequency, Pattern of Occurrence and Recurrence, and Optimal Strategy for Neck Dissection. Ann Surg 2003; 237(3): 399–407.

12. Ito Y, Kudo T, Kobayashi K et al. Prognostic Factors for Recurrence of Papillary Thyroid Carcinoma in the Lymph Nodes, Lung, and Bone: Analysis of 5,768 Patients with Average 10-year Follow-up. World J Surg 2012; 36(6): 1274–1278. Dostupné z DOI: <http://dx.doi.org/10.1007/s00268–012–1423–5>.

13. Chen Y, Sadow PM, Suh H et al. BRAFV600E Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Thyroid 2016; 26(2): 248–255. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2015.0391>.

14. Pyo JS, Sohn JH, Kng G. Detection of Tumor Multifocality Is Important for Prediction of Tumor Recurrence in Papillary Thyroid Microcarcinoma: A Retrospective Study and Meta-Analysis. J Pathol Transl Med 2016; 50(4): 278–286. Dostupné z DOI: <http://dx.doi.org/10.4132/jptm.2016.03.29>.